OLSSON, AG, P PAUCIULLO, Vladimír SOŠKA, P LULEY, RE PIETERS, G BRODA a B PALACIOS. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin Ther. UNITED STATES: ELSEVIER, 2001, roč. 23, č. 1, s. 45-61. ISSN 0149-2918.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
Název anglicky Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
Autoři OLSSON, AG, P PAUCIULLO, Vladimír SOŠKA, P LULEY, RE PIETERS, G BRODA a B PALACIOS.
Vydání Clin Ther, UNITED STATES, ELSEVIER, 2001, 0149-2918.
Další údaje
Typ výsledku Článek v odborném periodiku
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 2.721
Organizační jednotka Lékařská fakulta
Klíčová slova anglicky Fluvastatin; hypercholesterolemia
Změnil Změnil: prof. MUDr. Vladimír Soška, CSc., učo 34422. Změněno: 16. 3. 2011 13:38.
Anotace
The purpose of this study was to compare the lipid-lowering efficacy and tolerability of fluvastatin ER (80 mg once daily) versus fluvastatin immediate-release (IR) (40 mg once or twice daily). Of the 1183 patients enrolled, 695 were randomly assigned to treatment 346 to fluvastatin ER 80 mg QPM, 174 to fluvastatin IR 40 mg QPM, and 175 to fluvastatin IR 40 mg BID. Patients were well matched between groups, with a mean age of 56 years and body mass index of 27 kg/m2; 56.0% of patients (389/695) were female and 97.7% (679/695) were white. Fluvastatin ER 80 mg QPM lowered LDL-C levels significantly
Anotace anglicky
The purpose of this study was to compare the lipid-lowering efficacy and tolerability of fluvastatin ER (80 mg once daily) versus fluvastatin immediate-release (IR) (40 mg once or twice daily). Of the 1183 patients enrolled, 695 were randomly assigned to treatment 346 to fluvastatin ER 80 mg QPM, 174 to fluvastatin IR 40 mg QPM, and 175 to fluvastatin IR 40 mg BID. Patients were well matched between groups, with a mean age of 56 years and body mass index of 27 kg/m2; 56.0% of patients (389/695) were female and 97.7% (679/695) were white. Fluvastatin ER 80 mg QPM lowered LDL-C levels significantly
VytisknoutZobrazeno: 27. 5. 2024 05:52